Clinical Research Directory
Browse clinical research sites, groups, and studies.
MYeloma Resistance And Clonal Evolution
Sponsor: Nantes University Hospital
Summary
Multiple Myeloma (MM) is often associated with progression, temporary response to therapy and a high relapse rate over time resulting in a poor long-term prognosis. Because MM is classified as an incurable disease, therapeutic resistance is of great interest. However, knowledge about the biological mechanisms underlying resistance associated with MM therapies and about associated predictors remains poor. The MYRACLE cohort, a multicenter prospective cohort of patients with MM, is set up to address this limitation.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
1400
Start Date
2019-02-11
Completion Date
2049-02-11
Last Updated
2025-07-14
Healthy Volunteers
No
Conditions
Interventions
Prélèvement sanguin (2*4mL) ou médullaire (2mL)
Additional blood (2\*4mL) or bone marrow (2mL) sample depending on clinical presentation of disease
Data collection through questionnaires
Collection of quality of life and occupational exposure data via questionnaires
Locations (2)
La Roche sur Yon Hospital Departmental
La Roche-sur-Yon, France
Nantes University Hospital
Nantes, France